Q-omics provides the consensus-scored FAM200B profile across patient tissues and cancer cell-line models. FAM200B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, FAM200B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, FAM200B RNA expression shows 19,393 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCS, THCA, and UVM as cancer lineages where FAM200B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM200B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM200B survival associations across molecular data types. FAM200B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM200B RNA expression–survival associations across cancer types. High FAM200B expression shows favorable associations in UCS, BLCA, KIRP, OV, UCEC and PAAD. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for FAM200B RNA expression.
This table summarizes FAM200B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM200B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM200B shows lower tumor expression in THCA, KIRP, KICH, LUAD and KIRC and higher tumor expression in LIHC. The THCA box plot shows higher FAM200B RNA expression in normal versus tumor tissue (log2 FC = −1.063, t-test p < 0.001).
This table shows molecular features associated with FAM200B in patient tissues and cancer cell lines. In patient samples, FAM200B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM200B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
